Full Text View
Tabular View
No Study Results Posted
Related Studies
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
This study has been completed.
First Received: July 16, 2002   Last Updated: June 23, 2005   History of Changes
Sponsored by: NeoTherapeutics
Information provided by: NeoTherapeutics
ClinicalTrials.gov Identifier: NCT00041795
  Purpose

This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.


Condition Intervention Phase
Peripheral Nervous System Diseases
Chemotherapy-Induced Peripheral Neuropathy
 Drug: leteprinim potassium (Neotrofin)
 Phase II

MedlinePlus related topics: Cancer Neurologic Diseases Peripheral Nerve Disorders
Drug Information available for: Leteprinim potassium
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer

Further study details as provided by NeoTherapeutics:

Estimated Enrollment: 50
Study Start Date: January 2002
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy.
  • Sensory or motor neuropathy must be >/= grade 2 per Common Toxicity Criteria at baseline.
  • In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable.
  • Patient must have normal hematological cell counts.
  • Patient must have a life expectancy of >/= 3 months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00041795

Locations
United States, California
Providence St. Joseph Medical Center
Burbank, California, United States, 91505
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States, 94704
Providence Holy Cross Medical Center
Mission Hills, California, United States, 91345
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
NYU Medical Center
New York, New York, United States, 10016
United States, Tennessee
The Sarah Cannon Cancer Center
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
NeoTherapeutics
  More Information

Publications:
Grundman M, Farlow M, Peavy G, Kim HT, Capparelli E, Schultz AN, Salmon DP, Ferris SH, Mobs R, Thomas RG, Schafer K, Campbell K, Hake AM, Schoos B, Thal LJ. A phase I study of AIT-082 in healthy elderly volunteers. J Mol Neurosci. 2002 Jun;18(3):283-93.
Di Iorio P, Virgilio A, Giuliani P, Ballerini P, Vianale G, Middlemiss PJ, Rathbone MP, Ciccarelli R. AIT-082 is neuroprotective against kainate-induced neuronal injury in rats. Exp Neurol. 2001 Jun;169(2):392-9.
Rathbone MP, Middlemiss PJ, Gysbers JW, Andrew C, Herman MA, Reed JK, Ciccarelli R, Di Iorio P, Caciagli F. Trophic effects of purines in neurons and glial cells. Prog Neurobiol. 1999 Dec;59(6):663-90. Review.
Middlemiss PJ, Glasky AJ, Rathbone MP, Werstuik E, Hindley S, Gysbers J. AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. Neurosci Lett. 1995 Oct 20;199(2):131-4.

Study ID Numbers: 082-2001-005
Study First Received: July 16, 2002
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00041795     History of Changes
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Neuromuscular Diseases
Peripheral Nervous System Diseases
Motor Neuropathy

Additional relevant MeSH terms:
Neuromuscular Diseases
Peripheral Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on May 07, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services